GFT505, a dual PPARα–β/δ, demonstrated liver-protective effects on steatosis, inflammation, and fibrosis in animal models of NAFLD/NASH and liver fibrosis [75]. This evidence concerns the gene PPARA and metabolic dysfunction-associated steatotic liver disease.